Showing items 996-1020 of 1127 (46 Page(s) Totally)
<< < 35 36 37 38 39 40 41 42 43 44 > >>
View [10|25|50] records per page
| 臺大學術典藏 |
2016 |
Genetic alterations and their clinical implications in older patients with acute myeloid leukemia
|
Tsai C.-H.; Hou H.-A.; Tang J.-L.; Liu C.-Y.; Lin C.-C.; Chou W.-C.; Tseng M.-H.; Chiang Y.-C.; Kuo Y.-Y.; Liu M.-C.; Liu C.-W.; Lin L.-I.; Tsay W.; Yao M.; Li C.-C.; SHANG-YI HUANG; Ko B.-S.; Hsu S.-C.; Chen C.-Y.; Lin C.-T.; Wu S.-J.; Tien H.-F. |
| 國立臺灣大學 |
2015 |
TP53 mutations in de novo acute myeloid leukemia patients: longitudinal follow-ups show the mutation is stable during disease evolution
|
Hou, H-A; Chou, W-C; Kuo, Y-Y; Liu, C-Y; Lin, L-I; Tseng, M-H; Chiang, Y-C; Liu, M-C; Liu, C-W; Tang, J-L; Yao, M.; Li, C-C; Huang, S-Y; Ko, B-S; Hsu, S-C; Chen, C-Y; Lin, C-T; Wu, S-J; Tsay, W.; Chen, Y-C; Tien, H-F; 蔡偉; 林亮音; 姚明; 陳建源; 陳耀昌; 柯博升; 徐思淳; 田蕙芬; 劉敏枝; 陳宜君; 郭遠燁; 黃聖懿; 吳尚儒; 唐季祿; 周文堅; 侯信安 |
| 國立臺灣大學 |
2015 |
PIVOTAL BIOMARKER ALTERATIONS IN CYTARABINE-RESISTANT ACUTE MYELOID LEUKEMIA CELL LINES
|
Lin, L. I.; Lu, J. W.; Lim, P. P.; Lai, Y. L.; Chen, C. Y.; Tien, H. F.; 林亮音; 陳建源; 田蕙芬 |
| 臺大學術典藏 |
2015 |
A 3-microRNA scoring system for prognostication in de novo acute myeloid leukemia patients
|
Chuang, M.-K.;Chiu, Y.-C.;Chou, W.-C.;Hou, H.-A.;Chuang, E.Y.;Tien, H.-F.; Chuang, M.-K.; Chiu, Y.-C.; Chou, W.-C.; Hou, H.-A.; Chuang, E.Y.; Tien, H.-F.; ERIC YAO-YU CHUANG |
| 臺大學術典藏 |
2015 |
High incidences of invasive fungal infections in acute myeloid leukemia patients receiving induction chemotherapy without systemic antifungal prophylaxis: A prospective observational study in Taiwan
|
Tien H.-F.; Ko B.-S.; Chang S.-C.; Chen Y.-C.; Chen Y.-C.; Tsay W.; Huang S.-Y.; Chou W.-C.; Hou H.-A.; Wu S.-J.; Li C.-C.; Lin C.-T.; Hsu S.-C.; Tang J.-L.; Kung H.-C.; Lei W.-C.; Yao M.; UN-IN WU |
| 臺大學術典藏 |
2015 |
Higher decorin levels in bone marrow plasma are associated with superior treatment response to novel agent-based induction in patients with newly diagnosed myeloma - A retrospective study
|
Hsu S.-C.; Chou S.-C.; Chou W.-C.; Hou H.-A.; SHANG-JU WU; Tang J.-L.; Yao M.; Lin H.-H.; Huang S.-Y.; Ko B.-S.; Lu H.-Y.; Tsay W.; Tien H.-F. |
| 臺大學術典藏 |
2015 |
Risk factors and clinical outcomes of acute myeloid leukaemia with central nervous system involvement in adults
|
Cheng C.-L.; Tien H.-F.; Tsay W.; SHANG-JU WU; Ko B.-S.; Huang S.-Y.; Yao M.; Li C.-C.; Hou H.-A.; Fang W.-Q.; Chang C.-H.; Lin C.-T.; Tang J.-L.; Chou W.-C.; Chen C.-Y. |
| 臺大學術典藏 |
2015 |
GATA2 mutations in patients with acute myeloid leukemia-paired samples analyses show that the mutation is unstable during disease evolution
|
Lin C.-C.; Chou W.-C.; Lin Y.-C.; Kuo Y.-Y.; Hou H.-A.; Tien H.-F.; Chen Y.-C.; Tsay W.; Wu S.-J.; Hsu S.-C.; Ko B.-S.; Huang S.-Y.; MING YAO; Tang J.-L.; Liu C.-W.; Liu M.-C.; Chiang Y.-C.; Huang C.-F.; Tseng M.-H.; Liu C.-Y.; Chen C.-Y.; Lin L.-I. |
| 臺大學術典藏 |
2015 |
TP53 mutations in de novo acute myeloid leukemia patients: Longitudinal follow-ups show the mutation is stable during disease evolution
|
Hou H.-A.; Chou W.-C.; Tien H.-F.; Chen Y.-C.; Tsay W.; Wu S.-J.; Chen C.-Y.; Lin C.-T.; Hsu S.-C.; Ko B.-S.; Huang S.-Y.; Li C.-C.; Kuo Y.-Y.; Liu C.-Y.; Lin L.-I.; Tseng M.-H.; Chiang Y.-C.; Liu M.-C.; Liu C.-W.; Tang J.-L.; MING YAO |
| 臺大學術典藏 |
2015 |
Risk factors and clinical outcomes of acute myeloid leukaemia with central nervous system involvement in adults
|
MING YAO; Huang S.-Y.; Ko B.-S.; Wu S.-J.; Tsay W.; Tien H.-F.; Cheng C.-L.; Li C.-C.; Hou H.-A.; Fang W.-Q.; Chang C.-H.; Lin C.-T.; Tang J.-L.; Chou W.-C.; Chen C.-Y. |
| 臺大學術典藏 |
2015 |
TP53 mutations in de novo acute myeloid leukemia patients: Longitudinal follow-ups show the mutation is stable during disease evolution
|
Lin L.-I.; Kuo Y.-Y.; Liu C.-Y.; Chou W.-C.; Hou H.-A.; Tien H.-F.; Chen Y.-C.; Tsay W.; Lin C.-T.; Wu S.-J.; Chen C.-Y.; Hsu S.-C.; Tseng M.-H.; Chiang Y.-C.; Liu M.-C.; Liu C.-W.; Tang J.-L.; Yao M.; Li C.-C.; Huang S.-Y.; BOR-SHENG KO |
| 臺大學術典藏 |
2015 |
Higher decorin levels in bone marrow plasma are associated with superior treatment response to novel agent-based induction in patients with newly diagnosed myeloma - A retrospective study
|
Lu H.-Y.; Ko B.-S.; Chou S.-C.; Hsu S.-C.; Chou W.-C.; Hou H.-A.; Tang J.-L.; Wu S.-J.; Huang S.-Y.; Lin H.-H.; MING YAO; Tsay W.; Tien H.-F. |
| 臺大學術典藏 |
2015 |
Clinical and prognostic implications of roundabout 4 (Robo4) in adult patients with acute myeloid leukemia
|
Huang C.-F.; Tseng M.-H.; Chuang S.-S.; Chen C.-Y.; Lin C.-W.; Liu C.-Y.; Chou W.-C.; Kuo Y.-Y.; Lee M.-C.; Lai Y.-J.; Jhuang J.-Y.; Tang J.-L.; Hou H.-A.; Chen Y.-K.; Tien H.-F.; Chen Y.-C.; Tsay W.; Chiang Y.-C.; Lee F.-Y.; Liu M.-C.; Liu C.-W.; Yao M.; Huang S.-Y.; BOR-SHENG KO; Hsu S.-C.; Wu S.-J. |
| 國立臺灣大學 |
2014 |
Integration of cytogenetic and molecular alterations in risk stratification of 318 patients with de novo non-M3 acute myeloid leukemia
|
Hou, H-A; Lin, C-C; Chou, W-C; Liu, C-Y; Chen, C-Y; Tang, J-L; Lai, Y-J; Tseng, M-H; Huang, C-F; Chiang, Y-C; Lee, F-Y; Kuo, Y-Y; Lee, M-C; Liu, M-C; Liu, C-W; Lin, L-I; Yao, M.; Huang, S-Y; Ko, B-S; Hsu, S-C; Wu, S-J; Tsay, W.; Chen, Y-C; Tien, H-F; 林吉崇; 蔡偉; 李玢玉; 林亮音; 姚明; 陳建源; 陳耀昌; 柯博升; 徐思淳; 田蕙芬; 劉敏枝; 陳宜君; 郭遠燁; 黃聖懿; 吳尚儒; 唐季祿; 周文堅; 侯信安 |
| 國立臺灣大學 |
2014 |
Dynamics of ASXL1 mutation and other associated genetic alterations during disease progression in patients with primary myelodysplastic syndrome
|
Chen, T-C; Hou, H-A; Chou, W-C; Tang, J-L; Kuo, Y-Y; Chen, C-Y; Tseng, M-H; Huang, C-F; Lai, Y-J; Chiang, Y-C; Lee, F-Y; Liu, M-C; Liu, C-W; Liu, C-Y; Yao, M.; Huang, S-Y; Ko, B-S; Hsu, S-C; Wu, S-J; Tsay, W.; Chen, Y-C; Tien, H-F; 蔡偉; 李玢玉; 姚明; 陳建源; 陳耀昌; 柯博升; 徐思淳; 田蕙芬; 劉敏枝; 陳宜君; 郭遠燁; 黃聖懿; 吳尚儒; 唐季祿; 周文堅; 侯信安 |
| 國立臺灣大學 |
2014 |
Calreticulin mutation was rarely detected in patients with myelodysplastic syndrome
|
Hou, H-A; Kuo, Y-Y; Chou, W-C; Chen, P-H; Tien, H-F; 田蕙芬; 郭遠燁; 周文堅; 侯信安 |
| 國立臺灣大學 |
2014 |
Clinical Implications of the SETBP1 Mutation in Patients With Primary Myelodysplastic Syndrome and its Stability During Disease Progression
|
Hou, H. A.; Kuo, Y. Y.; Tang, J. L.; Chou, W. W.; Yao, M.; Lai, Y. L.; Lin, C. C.; Chen, C. Y.; Liu, C. Y.; Lee, M. C.; Tseng, M. H.; Huang, C. F.; Chiang, Y. C.; Lee, F. Y.; Liu, M. C.; Liu, C. Y.; Huang, S. Y.; Ko, B. S.; Wu, S. J.; Tsay, W.; Chen, Y. C.; Tien, H. F.; 林吉崇; 蔡偉; 李玢玉; 姚明; 陳建源; 柯博升; 田蕙芬; 陳宜君; 郭遠燁; 黃聖懿; 吳尚儒; 唐季祿 |
| 國立臺灣大學 |
2014 |
CABOZANTINIB IS SELECTIVELY CYTOTOXIC IN ACUTE MYELOID LEUKEMIA CELLS WITH INTERNAL TANDEM DUPLICATION OF FLT3 (FLT3-ITD)
|
Wang, A.; Lu, J. W.; Hou, H. A.; Chen, C. Y.; Hu, C. Y.; Ou, D. L.; Ko, Y. C.; Tien, H. F.; Lin, L. I.; 林亮音; 陳建源; 田蕙芬; 胡忠怡; 侯信安 |
| 國立臺灣大學 |
2014 |
ADRENOMEDULLIN, A HYPOXIA-RELATED PROTEIN, IS ASSOCIATED WITH PROGNOSIS OF ACUTE MYELOID LEUKEMIA
|
Lin, Y. F.; Hu, C. Y.; Ou, D. L.; Chen, C. Y.; Tien, H. F.; Ko, Y. C.; Lin, L. I.; 林亮音; 陳建源; 田蕙芬; 胡忠怡 |
| 臺大學術典藏 |
2014 |
Expression of cereblon protein assessed by immunohistochemicalstaining in myeloma cells is associated with superior response of thalidomide- and lenalidomide-based treatment, but not bortezomib-based treatment, in patients with multiple myeloma
|
MING YAO; Lin C.-W.; Lin H.-H.; Huang S.-Y.; Chou S.-J.; Chou W.-C.; Tsay W.; Chen C.-Y.; Hou H.-A.; Chen Y.-C.; Lu H.-Y.; Wu S.-J.; Tang J.-L.; Tien H.-F. |
| 臺大學術典藏 |
2014 |
The N-terminal CEBPA mutant in acute myeloid leukemia impairs CXCR4 expression
|
Tseng M.-H.; Li L.-Y.; Chen P.-H.; Chen Y.-K.; Hou H.-A.; Kuo Y.-Y.; Huang C.-F.; Lee F.-Y.; Liu M.-C.; Liu C.-W.; Chou W.-C.; Liu C.-Y.; Tang J.-L.; MING YAO; Tien H.-F. |
| 臺大學術典藏 |
2014 |
SF3B1 mutations in patients with myelodysplastic syndromes: The mutation is stable during disease evolution
|
Lin C.-C.; Hou H.-A.; Chou W.-C.; Kuo Y.-Y.; Wu S.-J.; Liu C.-Y.; Chen C.-Y.; Tseng M.-H.; Huang C.-F.; Lee F.-Y.; Liu M.-C.; Liu C.-W.; JIH-LUH TANG; Yao M.; Huang S.-Y.; Hsu S.-C.; Ko B.-S.; Tsay W.; Chen Y.-C.; Tien H.-F. |
| 臺大學術典藏 |
2014 |
Expression of cereblon protein assessed by immunohistochemicalstaining in myeloma cells is associated with superior response of thalidomide- and lenalidomide-based treatment, but not bortezomib-based treatment, in patients with multiple myeloma
|
SHANG-YI HUANG; Lin C.-W.; Lin H.-H.; Yao M.; Tang J.-L.; Wu S.-J.; Chen Y.-C.; Lu H.-Y.; Hou H.-A.; Chen C.-Y.; Chou W.-C.; Tsay W.; Chou S.-J.; Tien H.-F. |
| 臺大學術典藏 |
2014 |
Expression of cereblon protein assessed by immunohistochemicalstaining in myeloma cells is associated with superior response of thalidomide- and lenalidomide-based treatment, but not bortezomib-based treatment, in patients with multiple myeloma
|
Yao M.; Lin H.-H.; Lin C.-W.; Huang S.-Y.; Tien H.-F.; Tang J.-L.; SHANG-JU WU; Chen Y.-C.; Lu H.-Y.; Hou H.-A.; Chen C.-Y.; Chou W.-C.; Tsay W.; Chou S.-J. |
| 臺大學術典藏 |
2014 |
Prognostic implication of gene mutations on overall survival in the adult acute myeloid leukemia patients receiving or not receiving allogeneic hematopoietic stem cell transplantations
|
Hou H.-A.; Tang J.-L.; Chou S.-C.; Tien H.-F.; Chen Y.-C.; Tsay W.; Huang S.-Y.; Ko B.-S.; MING YAO; Chen C.-Y.; Chou W.-C.; Hu F.-C. |
Showing items 996-1020 of 1127 (46 Page(s) Totally)
<< < 35 36 37 38 39 40 41 42 43 44 > >>
View [10|25|50] records per page
